跳至主要内容
临床试验/NCT04272762
NCT04272762已完成不适用

A Randomized Sham-controlled Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation (The SHAM-PVI Study)

East Sussex Hospitals NHS Trust4 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2020年1月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
140
试验地点
4
主要终点
Atrial fibrillation burden using continuous monitoring

研究概览

简要总结

This is a double blinded randomised placebo-controlled trial comparing the effects of catheter ablation (Cryoablation) versus a placebo procedure on atrial fibrillation burden, symptoms and quality of life

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater than or equal to 18 years
  • Symptomatic paroxysmal or persistent atrial fibrillation despite at least one antiarrhythmic drug (AAD Type I or III, β-blocker or AAD intolerance).
  • Referred for catheter ablation

排除标准

  • Long term persistent AF (continuous episode lasting more than 1)
  • Prior left atrium catheter or surgical atrial fibrillation ablation
  • Patients with other arrhythmias requiring ablative therapy
  • Left atrium (LA) ≥5.5 cm
  • Any cardiac surgery or percutaneous coronary intervention (PCI) within three months prior to enrolment.
  • Awaiting cardiac surgery or PCI
  • Myocardial infarction within three months prior to enrolment.
  • Stroke or transient ischemic attack (TIA) within three months prior to enrolment
  • Unstable angina
  • Any significant congenital heart defect corrected or not (including atrial septal defects or PV abnormalities) but not including patent foramen ovale.
  • Any condition contraindicating chronic anticoagulation
  • Any untreated or uncontrolled hyperthyroidism or hypothyroidism
  • Severe chronic kidney disease (stage V, requiring or almost requiring dialysis, glomerular filtration rate (GFR) < 15 ml / min)
  • Patients with metallic prosthetic valves
  • Pregnant or breastfeeding women
  • Medical conditions limiting expected survival to <1 year
  • History of claustrophobia or panic attacks
  • Left ventricular ejection fraction (LVEF) less than 35%

研究组 & 干预措施

Placebo

Placebo Comparator

placebo procedure

干预措施: Placebo (Procedure)

Ablation

Active Comparator

pulmonary vein isolation

干预措施: Cryoablation (Procedure)

结局指标

主要结局

Atrial fibrillation burden using continuous monitoring

时间窗: 6 months

次要结局

  • Number of atrial arrhythmia ( symptomatic and asymptomatic) episodes stratified by length of episode(6 months)
  • Comparison of unscheduled use of health care services(6 months)
  • Time to asymptomatic atrial tachyarrhythmia stratified by length of episode(6 months)
  • Change in health related quality of life in each group (36-Item Short Form Survey Instrument )(Baseline and 6 months)
  • Comparison of medical treatment ( Antiarrhythmic drug use)(6 months)
  • Number of procedure related complications / adverse events(6 months)
  • Change in AF specific quality of life score between each group (AF-PROMS)(Baseline and 6 months)
  • Time to symptomatic atrial tachyarrhythmia stratified by length of episode(6 months)

研究者

发起方
East Sussex Hospitals NHS Trust
申办方类型
Other
责任方
Principal Investigator
主要研究者

Rick Veasey

Principal Investigator

East Sussex Hospitals NHS Trust

研究点 (4)

Loading locations...

相似试验